Vicore Pharma Holding AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was SEK 63.56 million compared to SEK 68.48 million a year ago. Basic loss per share from continuing operations was SEK 0.58 compared to SEK 0.95 a year ago.
For the nine months, net loss was SEK 199.05 million compared to SEK 227.72 million a year ago. Basic loss per share from continuing operations was SEK 2.18 compared to SEK 3.17 a year ago.